| Autor: |
Chiarini A; Human Histology & Embryology Section, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, 37134 Verona, Italy., Gui L; Department of Neurology, Southwest Hospital, Chongqing 400038, China., Viviani C; Human Histology & Embryology Section, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, 37134 Verona, Italy., Armato U; Human Histology & Embryology Section, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, 37134 Verona, Italy., Dal Prà I; Human Histology & Embryology Section, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, 37134 Verona, Italy. |
| Abstrakt: |
Increasingly prevalent acute and chronic human brain diseases are scourges for the elderly. Besides the lack of therapies, these ailments share a neuroinflammation that is triggered/sustained by different innate immunity-related protein oligomers called inflammasomes. Relevant neuroinflammation players such as microglia/monocytes typically exhibit a strong NLRP3 inflammasome activation. Hence the idea that NLRP3 suppression might solve neurodegenerative ailments. Here we review the recent Literature about this topic. First, we update conditions and mechanisms, including RNAs, extracellular vesicles/exosomes, endogenous compounds, and ethnic/pharmacological agents/extracts regulating NLRP3 function. Second, we pinpoint NLRP3-activating mechanisms and known NLRP3 inhibition effects in acute (ischemia, stroke, hemorrhage), chronic (Alzheimer's disease, Parkinson's disease, Huntington's disease, MS, ALS), and virus-induced (Zika, SARS-CoV-2, and others) human brain diseases. The available data show that (i) disease-specific divergent mechanisms activate the (mainly animal) brains NLRP3; (ii) no evidence proves that NLRP3 inhibition modifies human brain diseases (yet ad hoc trials are ongoing); and (iii) no findings exclude that concurrently activated other-than-NLRP3 inflammasomes might functionally replace the inhibited NLRP3. Finally, we highlight that among the causes of the persistent lack of therapies are the species difference problem in disease models and a preference for symptomatic over etiologic therapeutic approaches. Therefore, we posit that human neural cell-based disease models could drive etiological, pathogenetic, and therapeutic advances, including NLRP3's and other inflammasomes' regulation, while minimizing failure risks in candidate drug trials. |
